ChromoGenics AB (publ) is a “Euroclear company” and the shares are electronically registered, the share register is kept by Euroclear Sweden AB, Klarabergsviadukten 63, 111 64 Stockholm.
The company’s shares are listed on Nasdaq First North Growth Market since March 23, 2017.
All shares are of the same class, have equal rights to share the Company’s assets and profits and have one vote each without any special limitations.
Share capital on June 31, 2023 amounted to SEK 35 011 396,130 distributed over 411 898 778 shares with a quota value of SEK 0.085 per share.
ChromoGenics’ shares and warrants are traded on Nasdaq First North Growth Market.
Short name: CHRO
Only one share category exists.
In Swedish companies, the dividend must be proposed by the Board and decided by the Annual General Meeting in accordance with the Companies Act and the Articles of Association.
In consideration of proposals for future dividends, the Board will consider several factors, including the Company’s operations, operating profit and financial position, current and expected liquidity needs, expansion plans, contractual constraints and other significant factors.
ChromoGenics is in a development and expansion phase and therefore no dividend has ever been paid. At present, the Board intends to continue to allow the Company to balance any profits to finance the growth and operation of the business and consequently does not predict that any cash dividends will be paid in the foreseeable future.
Each share in ChromoGenics entails one (1) vote at the Annual General Meeting.
Largest owners as of May 31, 2023.